{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T15:46:16Z","timestamp":1782747976435,"version":"3.54.5"},"reference-count":41,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2026,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Translation inhibitors have been shown to accelerate acute myeloid leukemia (AML) cell apoptosis and regulate Akt activity and the Bcl\u20102 family, suggesting their potential benefit when combined with venetoclax and cytarabine in de novo AML patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The authors conducted a multicenter, open\u2010label, single\u2010arm study to assess the efficacy and safety of a venetoclax\u2013cytarabine\u2010based induction regimen incorporating a clinically available translation inhibitor in adult patients newly diagnosed with AML in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 52 cases (median age, 48.5 years; range, 18\u201360) were treated, with poor risk in 27% (14 of 52) of patients. The overall response rate was 90% (95% CI, 79\u201397) after one cycle of the regimen with 46 patients in composite complete remission. With a median follow\u2010up of 816 days (interquartile range, 418\u20131143), the estimated 1\u2010year overall survival (OS) and event\u2010free survival (EFS) were both 81% (95% CI, 71\u201392). After induction chemotherapy, patients experienced decreases in CD4\n                      <jats:sup>+<\/jats:sup>\n                      naive, CD8\n                      <jats:sup>+<\/jats:sup>\n                      naive, Th2, and CD19\n                      <jats:sup>+<\/jats:sup>\n                      cells, along with increases in CD4\n                      <jats:sup>+<\/jats:sup>\n                      TEM, Th1, natural killer cells, and a higher Th1\/Th2 ratio in both peripheral blood and bone marrow (BM), whereas BM\u2010specific changes included a decrease in CD8\n                      <jats:sup>+<\/jats:sup>\n                      naive cells\u00a0and lower IL\u201010 levels post\u2010treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This venetoclax\u2013cytarabine regimen incorporating a translation inhibitor demonstrated efficacy and was well\u2010tolerated in young adult patients with de novo AML, achieving high complete remission rates and encouraging OS and EFS. The induced immune\u2010cell and cytokine shifts provide deeper insights into integrating translational inhibition with BCL2\u2010targeted therapies and warrant further investigation in randomized controlled trials. This trial was registered at ChiCTR.org.cn as ChiCTR2100048208.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.70432","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T16:29:29Z","timestamp":1778603369000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A venetoclax\u2010cytarabine\u2010based induction regimen incorporating a translation inhibitor for adult patients with de novo acute myeloid leukemia"],"prefix":"10.1002","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0657-7738","authenticated-orcid":false,"given":"Xiao\u2010Hua","family":"Luo","sequence":"first","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Chongqing Medical University  Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na\u2010Na","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Chongqing Medical University  Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Chongqing Medical University  Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hematology Southwest Hospital Third Military Medical University (Army Medical University)  Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Chongqing Medical University  Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang\u2010Nian","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology Southwest Hospital Third Military Medical University (Army Medical University)  Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Chongqing Medical University  Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai\u2010Xia","family":"Pei","sequence":"additional","affiliation":[{"name":"The Center for Clinical Molecular Medical Detection The First Affiliated Hospital of Chongqing Medical University  Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhan","sequence":"additional","affiliation":[{"name":"The Center for Clinical Molecular Medical Detection The First Affiliated Hospital of Chongqing Medical University  Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Chongqing Medical University  Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian\u2010Bin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Chongqing Medical University  Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0904544"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.72.8618"},{"key":"e_1_2_9_4_1","unstructured":"SEER data base: cancer stat facts: leukemia \u2014 acute myeloid leukemia (AML). Accessed November 22 2025.https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2012971"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.03736"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103026(21)00192\u20107"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103026(22)00106\u20105"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20100"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102010\u201001\u2010262808"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.149"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202115203"},{"issue":"1","key":"e_1_2_9_13_1","first-page":"27","article-title":"An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia","volume":"4","author":"Lasry A","year":"2023","journal-title":"Nat Cancer"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(13)70152\u20109"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.02836"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010021\u201001131\u20106"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253\u20102727.2021.08.001"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010021\u201001159\u20102"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn121090\u201020240611\u201000218"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867"},{"key":"e_1_2_9_21_1","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) v6.0","author":"National Cancer Institute (NCI)","year":"2025"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2021.01.008"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.08.002"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020102"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.286832"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26601"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103026(22)00076\u2010x"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164\u2010023\u201000409\u2010y"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010023\u201001437\u20101"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.Ccr\u201024\u20101332"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201015\u20101191"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164\u2010021\u201000201\u2010w"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326\u20106066.cir\u201019\u20100516"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009081"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.cd\u201021\u20101026"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419\u2010021\u201004285\u20104"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010024\u201001064\u20100"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.cd\u201019\u20100759"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004861"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.03.030"},{"key":"e_1_2_9_41_1","article-title":"Venetoclax acts as an immunometabolic modulator to potentiate adoptive NK cell immunotherapy against leukemia","author":"Wang Y","year":"2024","journal-title":"Cell Rep Med"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1513257"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70432","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.70432","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70432","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T15:15:58Z","timestamp":1782746158000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.70432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,5,15]]}},"alternative-id":["10.1002\/cncr.70432"],"URL":"https:\/\/doi.org\/10.1002\/cncr.70432","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"2025-12-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70432"}}